Checkpoint inhibitors in immunotherapy of ovarian cancer

Blockade of the B7-H1/PD-1 Pathway as a Basis for Combination Anticancer Therapy

(2014) Mario Sznol   CANCER JOURNAL

Programmed death-1 pathway in cancer and autoimmunity

(2014) Ariel Pedoeem et al.   CLINICAL IMMUNOLOGY

The perspective of immunotherapy

(2014) Christian U. Blank   CURRENT OPINION IN ONCOLOGY

Immune Checkpoint Blockade

(2014) Jarushka Naidoo et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs

(2014) Lei Lu et al.   Journal of Translational Medicine

Ipilimumab augments antitumor activity of bispecific antibody-armed T cells

(2014) Hiroshi Yano et al.   Journal of Translational Medicine

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

(2014) Caroline Robert et al.   LANCET

PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer

(2014) Zhiqiang Guo et al.   PLoS One

Role of epithelial to mesenchymal transition proteins in gynecological cancers: pathological and therapeutic perspectives

(2014) Xiao-mei Zhou et al.   TUMOR BIOLOGY

Novel anti-melanoma treatment: focus on immunotherapy

(2014) Meng-Ze Hao et al.   Chinese Journal of Cancer

Immune checkpoints in cancer clinical trials

(2014) Elad Sharon et al.   Chinese Journal of Cancer

Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies

(2014) Maria Muccioli et al.   Frontiers in Immunology

AttenuatedListeria monocytogenesreprograms M2-polarized tumor-associated macrophages in ovarian cancer leading to iNOS-mediated tumor cell lysis

(2014) Patrick H Lizotte et al.   OncoImmunology

Antibody-based immunotherapy for ovarian cancer: where are we at?

(2013) B. W. C. Tse et al.   ANNALS OF ONCOLOGY

Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours

(2013) M Millward et al.   BRITISH JOURNAL OF CANCER

Immune Checkpoint Inhibitors as Novel Targets for Renal Cell Carcinoma Therapeutics

(2013) Alexandra Bailey et al.   CANCER JOURNAL

Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control

(2013) C. Robert et al.   CLINICAL CANCER RESEARCH

PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction

(2013) K. Abiko et al.   CLINICAL CANCER RESEARCH

Coinhibitory molecules in cancer biology and therapy

(2013) Simone Mocellin et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Checkpoint blocking antibodies in cancer immunotherapy

(2013) Chrisann Kyi et al.   FEBS LETTERS

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

(2013) Antoni Ribas et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma

(2013) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy

(2013) Margaret K. Callahan et al.   JOURNAL OF LEUKOCYTE BIOLOGY

At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy

(2013) Andrew M. Intlekofer et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

(2013) Jason R Westin et al.   LANCET ONCOLOGY

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combinatorial PD-1 Blockade and CD137 Activation Has Therapeutic Efficacy in Murine Cancer Models and Synergizes with Cisplatin

(2013) Huafeng Wei et al.   PLoS One

Cancer Immunotherapy

(2013) Fumito Ito et al.   Surgical Oncology Clinics of North America

Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer

(2013) J. R. Brahmer et al.   Cancer Immunology Research

Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

(2013) M. J. Selby et al.   Cancer Immunology Research

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor-Infiltrating Programmed Death Receptor-1+ Dendritic Cells Mediate Immune Suppression in Ovarian Cancer

(2011) J. Krempski et al.   JOURNAL OF IMMUNOLOGY

Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4

(2011) O. S. Qureshi et al.   SCIENCE

Immunotherapy in prostate cancer: Emerging strategies against a formidable foe

(2011) Marijo Bilusic et al.   VACCINE

Opportunistic autoimmune disorders

(2010) Yi-chi M. Kong et al.   Annals of the New York Academy of Sciences

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

(2008) R. Berger et al.   CLINICAL CANCER RESEARCH

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

(2008) F. S. Hodi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA